Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Hepatocellular 25Carcinoma, Non-Small-Cell Lung 22Small Cell Lung Carcinoma 14Lung Neoplasms 14Neoplasms 11Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Melanoma 5Carcinoma, Transitional Cell 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Stomach Neoplasms 3Solid Tumors 3Sarcoma, Alveolar Soft Part 3Sarcoma 3Liver Neoplasms 3Glioblastoma 3Extensive Stage Lung Small Cell Carcinoma 3Treatment-Refractory Solid Tumors 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Esophageal Neoplasms 2

Interventions

pembrolizumab 45Carboplatin 35Paclitaxel 28Specimen Handling 19Cyclophosphamide 17Capecitabine 16Magnetic Resonance Spectroscopy 15Gemcitabine 14sacituzumab govitecan 12Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11olaparib 9Doxorubicin 9Albumin-Bound Paclitaxel 9Nivolumab 7fludarabine 6eribulin 5Radiotherapy 5Docetaxel 5Cisplatin 5durvalumab 4atezolizumab 4Immunoglobulin G 4Fulvestrant 4Drug Therapy 4Bevacizumab 4veliparib 3toripalimab 3sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × atezolizumab × 90 days × Clear all
NCT05498896 2026-05-08

BARBICAN

Queen Mary University of London

Phase 2 Active not recruiting
146 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Dana-Farber Cancer Institute

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03756298 2026-04-23

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Center, Korea

Phase 2 Active not recruiting
284 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡